Development of human monoclonal antibodies and uses thereof

Abstract

The present invention provides a heteromyeloma cell other than B6B11, capable of producing a trioma cell when fused with a human lymphoid cell, wherein the trioma cell is capable of producing a tetroma cell capable of producing a monoclonal antibody having specific binding affinity for an antigen, when fused with a second human lymphoid cell, the second human lymphoid cell being capable of producing antibody having specific binding affinity for the antigen. The invention provides a trioma cell fusion partner which does not produce any antibody obtained by fusing a hetermomyeloma cell which does not produce any antibody with a human lymphoid cell. The invention provides a tetroma cell capable of producing a monoclonal antibody having specific binding affinity for an antigen obtained by fusing a trioma cell which does not produce any antibody with a human lymphoid cell capable of producing antibody having specific binding affinity for the antigen. The invention provides a method of producing a monoclonal antibody specific for an antigen associated with a condition. The invention provides a method of identifying an antigen associated with a condition using the trioma fusion partner. The invention provides a method of diagnosing a condition using the trioma fusion partner. The invention provides a method for preventing a condition. Compositions and therapeutic compositions are also provided, using monoclonal antibodies produced using the trioma fusion partner.

1 . (canceled)  
   
   
       2 . A trioma cell which does not produce any antibody obtained by fusing a heteromyeloma cell which does not produce any antibody with a human lymphoid cell.  
   
   
       3 . The trioma cell of  claim 2 , wherein the heteromyeloma cell is the cell designated B6B11 (ATCC accession number HB-12481).  
   
   
       4 . The trioma cell of  claim 2 , wherein the heteromyeloma cell is a B6B11-like cell.  
   
   
       5 . The trioma cell of  claim 2 , wherein the human lymphoid cell is a myeloma cell.  
   
   
       6 . The trioma cell of  claim 2 , wherein the human lymphoid cell is a splenocyte or a lymph node cell.  
   
   
       7 . The trioma cell of  claim 2 , wherein the trioma is the cell designated MFP-2 (ATCC accession number HB-12482).  
   
   
       8 - 28 . (canceled)  
   
   
       29 . A method of producing a monoclonal antibody comprising: 
 (a) fusing a lymphoid cell capable of producing antibody with the trioma cell of  claim 2 , thereby forming tetroma cells; and    (b) incubating the tetroma cells formed in step (a) under conditions permissive to the production of antibody by the tetroma cell, thereby producing the monoclonal antibody.    
   
   
       30 . A method of producing a monoclonal antibody specific for an antigen associated with a condition in a subject comprising: 
 (a) fusing a lymphoid cell capable of producing antibody with the trioma cell of  claim 2 , thereby forming tetroma cells;    (b) incubating the tetroma cells formed in step (a) under conditions permissive for the production of antibody by the tetroma cells;    (c) selecting a tetroma cell producing a monoclonal antibody;    (d) contacting the monoclonal antibody of step (c) with (1) a sample from a subject with the condition or (2) a sample from a subject without the condition under conditions permissive to the formation of a complex between the monoclonal antibody and the sample;    (e) detecting the complex formed between the monoclonal antibody and the sample;    (f) determining the amount of complex formed in step (e); and    (g) comparing the amount of complex determined in step (f) for the sample from the subject with the condition with the amount determined in step (f) for the sample from the subject without the condition, a greater amount of complex formation for the sample from the subject with the condition indicating that a monoclonal antibody specific for the antigen specific for the condition is produced.    
   
   
       31 . The method of  claim 29 , step (a) further comprising freezing the lymphoid cell.  
   
   
       32 . The method of  claim 29 , step (b) further comprising incubating the selected tetroma cells under conditions permissive for cell replication.  
   
   
       33 . The method of  claim 32 , wherein tetroma replication is effected in vitro or in vivo.  
   
   
       34 . The method of  claim 29 , wherein the trioma cell is the cell designated MFP-2 (ATCC Accession No. HB-12482).  
   
   
       35 - 78 . (canceled)